An accurate tissue-based test
to predict non-evolutive localized prostate cancer (LPCa)
- Use of next generation sequencing (NGS) technology for gene expression analysis
- A sensitive quantification of RNA biomarkers of interest
- A software for an accurate rendering of results
Clinical validation in 2021
Training set: preliminary results
Kamoun A, Cancel-Tassin G, Formont g, elarouci N, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology. 2018 August 1814-1821.